Please login to the form below

Not currently logged in
Email:
Password:

Reig Jofre and LeanBio launch Syna Therapeutics

The new company will focus on the development of biosimilars

Reig JofrePharmaceutical group Reig Jofre has entered into a strategic alliance with LeanBio, a four-year-old biotech company, to launch a new company focused on the development of biosimilars and ‘innovative’ molecules.

Much like its parent companies, Syna Therapeutics will be headquartered in Barcelona, Spain, where LeanBio’s founder Dr Andreu Soldevila will take the helm of the new business while Gabriel Roig becomes president of the board of directors.

Hoping to tap into a global biosimilar market of around €1,000m, Syna Therapeutics’ expertise will comprise of LeanBio’s biological development experience and Reig Jofre’s capability in formulation, stabilisation and pharmaceutical development of biological and injectable products.

Dr Soldevila said: “The development of a biosimilar is highly complex and one of the most important technological challenges of recent years.

“Bringing patients closer to biological treatments in a more sustainable way for national health systems means in addition a great social impact in a huge market.”

Syna Therapeutics will have to finance €9m to carry out the early stages of development, with the founding partners both contributing the initial capital estimated at €2m.

The new company has said it will also consider the entry of new financial or industrial commercial partners to support clinical development in its final stages.

Article by
Gemma Jones

26th March 2018

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
wethepeople

wethepeople are bringing human appeal back to brand communications. Our approach allows us to create strategies, ideas and experiences that...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics